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Objective: To describe postoperative complications and long-term 
outcomes of completion pneumonectomy and highlight prognostic 
factors.
Method: We retrospectively reviewed the records of 46 patients 
(38 men, 8 women) who underwent completion pneumonec-
tomy for lung cancer between 1995 and 2009 in one of two 
thoracic surgery departments. Most were current or former 
smokers (n = 41; 89%) and did not undergo chemotherapy 
(n = 38; 83%) or radiotherapy (83%) before surgery.
Results: Complications after surgery were respiratory failure (n = 11; 
24.4%), bronchopleural fistula (n = 6; 13%, with no side preference), 
and empyema (n = 6; 13%). Blood transfusion was necessary for 
43% of the cases (n = 20). The day 90 death rate was 15.2% (n = 7). 
Postoperative staging showed mostly limited disease. Ten patients 
(21.7%) underwent operation for a second primary cancer, 25 for 
local recurrence (54.3%), five for microscopically incomplete resec-
tion, and six for other reasons.Median overall survival after com-
pletion surgery was 30 months (median follow-up: 46.5 months). 
Among the 15 living patients (33%), 11 are free of disease (24%). 
In a Cox regression model, factors negatively influencing over-
all survival were: age older than 65 years (odds ratio [OR] = 2.47; 
p = 0.012), current smoker status (OR = 2.285; p = 0.033), postop-
erative pulmonary (OR = 5.144; p = 0.004), cardiac (OR = 3.404; 
p = 0.033), or parietal wound complications (OR = 5.439; p = 0.016).
Conclusion: Despite its increased postoperative complications and 
mortality compared with standard pneumonectomy, completion 
pneumonectomy offers encouraging long-term results. Five main 
factors seem predictive of shorter overall survival.
Key Words: Completion pneumonectomy, Lung cancer, 
Bronchopleural fistula, Postoperative hemorrhage, Thoracic surgery.
(J Thorac Oncol. 2012;7: 1556–1562)
Completion pneumonectomy (CP) refers to the complete removal of remaining lung after an initial ipsilateral par-
tial resection.1 Compared with standard pneumonectomy, CP 
runs a greater risk of postoperative morbidity and mortality, 
largely because of the technical difficulties induced by the 
need to free all the remaining lung tissue and iteratively dis-
sect the lung hilum.2
Most of the studies published to date have confirmed 
these characteristics,3–7 and thus recommend that this 
intervention be performed only by experienced surgeons8,9 
on carefully selected patients.10,11 Some data suggest that 
postoperative mortality may be greater in patients operated 
for benign lesions compared with those operated for 
neoplasia,2,8,12,13 although it should be noted that this facet 
remains controversial.14–16 There are currently little data on 
factors influencing long-term survival and postoperative 
mortality. Thus our objective in this retrospective multicenter 
study was to assess survival in patients who underwent CP 
for neoplastic events only (primary or metastatic to the lung) 
and report factors associated with survival or postoperative 
mortality.
PATIENTS AND METHODS
Methods
All CP patient cases from January 1, 1995, to December 
31, 2009, in two thoracic surgery departments in Lyon (France) 
were reviewed. Only those cases falling within the neoplastic 
context were retained for and included in this retrospective 
study, that is one or both of the surgical interventions was/
were for neoplasia. Cases in which both surgical interventions 
were for nonmalignant causes were excluded, as were those 
with incomplete files. All data used in the study were retrieved 
from the archived patient medical files. When lacking in the 
medical files, survival data (dates of death) were collected 
from patients’ primary care physicians or birthplace city hall 
records. In addition to habitual demographic data and data on 
the neoplastic disease and pertinent patient history, we also 
gathered information specific to the surgery and postoperative 
complications. Median follow-up was 46.5 months (0–178) 
since CP, and 102, 7 months since first surgery (12–320).
Statistical Analyses
Statistical analyses were performed with SPSS v17.0 
(IBM Corp., Armonk, NY). Proportion comparisons were 
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done with Pearson’s χ2 test or Fisher’s F test as needed. 
The Kaplan–Meier method was used for survival analyses. 
Survival comparisons were calculated using the log-rank test. 
For multivariate analyses, Cox regression was used for factors 
linked to survival and binary logistic regression for postopera-
tive mortality. A p value of 0.05 or less was considered statisti-
cally significant.
Population
Forty-six of the 51 initially reviewed case files met the 
study inclusion criteria (2 exclusions for nonmalignancy and 
3 for incomplete files).
Characteristics of included patients are provided in 
Table 1. Forced expiratory volume (FEV1) was evaluated for 
all patients. If preoperative FEV1 was inferior to 80% and/or 
diffusion capacity inferior to 80%, a pulmonary ventilation/
perfusion scan was performed to evaluate participation of the 
removed lung. A predictive postoperative FEV1 less than 35% 
was considered as a contraindication for surgery. Exercise 
testing before operation was not realized in this series.
Operative Technique
The first task of the surgeon was to carefully read the 
surgical report on the patient’s previous procedure. All opera-
tions were done by reopening the previously used thoracot-
omy incision. Section of the posterior part of the fifth rib, to 
provide easier access to the pleural space, was done if neces-
sary. Excessive bleeding from the chest wall was prevented by 
mobilization of the lung through the intrapleural space when-
ever possible. This part of the procedure was particularly dif-
ficult and hemorragic when the first operation had been done 
extrapleurally.
Once the lung was freed, the pulmonary blood vessels 
were ligated extrapericardially if possible (Table 2). The peri-
cardium was opened when extrapericardial dissection was not 
possible. If the pericardial cavity was completely obliterated, 
we tried to isolate and divide the bronchus first and then ligate 
the pulmonary blood vessels.
The bronchus was transacted as close as the tracheal 
bifurcation as possible. The stump was almost never cov-
ered with a flap when surgery was performed on the left side, 
because it was buried deeply under the aorta. On the right 
side, it was often covered with viable tissue (n = 17) such as 
pleura from the arch of the azygos, pericardium, or intercostal 
muscle. In many cases, fibrin glue was generously applied on 
the bronchial stump.
RESULTS
Events resulting in CP and technical aspects are pro-
vided in Table 2. Histologically, adenocarcinoma was the most 
common entity (45.2%; n = 21). Anatomical pathology find-
ings were identical between the initial surgery and CP in more 
than three quarters of the cases (76.9%; n = 30). Expressed by 
the tumor, lymph node, and metastasis classification (7th edi-
tion, 2009),17 the neoplasms were generally small (T1: 30.8%, 
n = 12; T2: 48.7%, n = 19), without mediastinal lymph node 
involvement (N0: 79.5%; n = 31) and without metastasis (M0: 
97.5%; n = 39). Consequently, there were more frequently 
early stages (stage I: 55%, n = 22; II: 22.5%, n = 9; IIIA: 
20%, n = 8) than late ones (stage IIIB: 0; IV: 2.5% [1 patient 
presenting pleural carcinosis]). Long-term survival according 
to the stage is presented in Figure 1. Most patients (68.9%; 
n = 31) did not receive adjuvant treatments after CP.
Table 3 presents the principle postoperative outcomes. 
Causes of mortality in the first 90 days were: bronchopleural 
fistula (42, 8%: n = 3), respiratory failure (28, 6%; n = 2), 
and unclear (28, 6%; n = 2: 1 death at home in a context of 
acute respiratory failure and 1 in intensive care attributed to 
multiple cerebral septic emboli). Bronchopleural fistula (BPF) 
caused the death of three of the six affected patients. The three 
others were successfully treated, two by endoscopic applica-
tion of tissue adhesive and one by thoracostomy and latissi-
mus dorsi myoplasty. In this series, the mean hospital stay was 
19.6 days (range, 7–169), of which a mean 5.2 days were spent 
with a chest drain in place.
At the end of the follow-up period (September 1, 2010) 
15 patients (32.6%) were still alive. Five-year actuarial sur-
vival was 47%. The causes of death for the 31 other patients 
were: lung cancer (30.4%; n = 14), CP (15.2%, n = 7; cor-
responding to the day-90 [D90] mortality rate), and other or 
unknown (21.8%; n = 10). The median of post-CP progres-
sion-free survival (PFS) was 16 months (95% confidence 
interval [CI] = 9.614–22.386). Twenty-one patients (50%) 
presented recurrence at the end of the follow-up period.
In univariate analyses, no demographic or preoperative 
criteria (including cancer stage and comorbidity) was found 
to be associated with postoperative mortality before D90 
(Table 4). Factors associated with risk of death at D90 were 
inferior lobe (left or right) CP (43.6% versus 100%; p = 0.01), 
postoperative, respiratory complications and/or more than 
two complications (12.8% versus 100%; p < 0.0001; – 28.2% 
versus 83.3%; p = 0.017, respectively), and fistula formation 
(7.7% versus 50%; p = 0.024). Factors influencing overall 
survival were also analyzed. Again in univariate analyses, 
factors significantly associated with improved survival were: 
age less than 65 years (65 versus 21 months; p = 0.013), never 
or former smoker status (44 versus 8 months; p = 0.011), 
lymphadenectomy during CP (44 versus 6 months; p = 0.015), 
absence of respiratory complications (44 versus 0 months; 
p < 0.0001), and absence of thoracotomy wound complications 
(44 versus 4 months; p = 0.023). Female sex (p = 0.052), 
absence of cardiac complications (p = 0.053) and absence of 
reintubation (p = 0.069) provided a nonsignificant tendency 
toward better survival. The type of CP (inferior lobe versus 
other) was not found to be associated with overall survival.
Multivariate analyses were done with demographic 
and postoperative criteria, significance showing a trend for 
increased mortality in univariate analysis (Table 4). Factors 
associated with postoperative mortality were: pulmonary 
complication (p < 0.00001), BPF (p = 0.024), more than 
two postoperative complications (p = 0.017), and CP on the 
lower lobe (p = 0.01). Age younger than 65 years remained a 
factor of good prognosis (hazard ratio [HR] = 2.665 [1.139–
6.238], p = 0.024) as did never or former smoker status 
(HR = 2.270 [1.058–4.870], p = 0.035). For postopera-
tive criteria, the absence of respiratory, cardiac and wound 
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complications were all good prognosis factors with respective HR 
of 5.144 (1.662–15.919; p = 0.004), 3.404 (1.101–10.527; 
p = 0.033), and 5.439 (1.373–21.539; p = 0.016). No addi-
tional factors associated with improved overall survival were 
found when postoperative deaths (< D90) were excluded. 
Similarly, smoking status was the only factor significantly 
associated with overall survival from the date of the initial 
surgery. None of these factors were associated with PFS. 
Disease-descriptive factors (T > 1, N > 0, and stage > 1) were 
associated with neither overall survival nor PFS, probably 
because of the size of the test population. For perioperative 
factors, only lymphadenectomy during CP was significantly 
associated in nonadjusted analysis, but its association disap-
peared after adjustment for stage and lymph node status. For 
postoperative complications, after exclusion of postopera-
tive deaths, only wound complications remained significantly 
associated with survival (HR: 5.793 [1.219–27.538]; p = 0.027). 
TABLE 1. Main Characteristics of the Population
Characteristic n %
Demographic criteria
Sex
Male 38 82.6
Female 8 17.4
Mean age (yrs) (± SD) 59.2 (± 9)
Smoking status
Nonsmoker 5 10.9
Former smokera 24 52.2
Current smoker 17 37
Mean FEV1 (± SD) in % (n = 41) 71.1% (± 13.46%)
Mean predicted postoperative lung volume 
(±SD) in % on pulmonary ventilation/
perfusion scan (n = 21)
63.7% (± 16.79%)
First surgery characteristics
Cause for first surgery
Primary lung cancer 43 93.4
Lung metastases 2 4.4
Aspergilloma 1 2.2
Pathology (n = 45)
Adenocarcinoma 17 37.8
Squamous cell carcinoma 25 55.6
Large cell carcinoma 1 2.2
Typical carcinoid 1 2.2
Fibrosarcoma 1 2.2
Lymph node dissection (n = 43) 42 97.7
Mean duration between first surgery  
and CP (± SD; max–min)
54.6 mos (±64.9; 
0–310)
Preoperative comorbidities before CP
Number of comorbidities
None 10 21.7
≤ 2 31 67.5
> 2 5 10.8
Type of comorbidity
COPDb 26 70.3
Coronary artery disease 8 17.4
Heart failure 1 2.2
Diabetes 8 17.4
Renal failurec 5 13.2
Corticosteroid or IS use 1 2.2
Peripheral arterial disease 2 4.3
Preoperative antineoplastic treatment
Chemotherapy < 3 mos 8 17.4
Mediastinal radiotherapy (any time) 8 17.4
ASA score
≤2 37 80.4
≥3 9 19.6
a Defined as quit smoking 12 months ago or longer.
bDefined as FEV1/VC < 70%.
cDefined as creatinine clearance < 60 ml/mn.
FEV1, forced expired volume in 1 second; COPD, chronic obstructive pulmonary 
disease; CP, completion pneumonectomy; IS, immunosuppressive treatment;  
ASA, American Society of Anesthesiology.
TABLE 2. Main Characteristics of the Completion Surgery
Characteristic N %
Cause of the CP
Malignant disease 42 91.2
Secondary primary NSCLCa 10 (1 carcinoid) 21.7
Recurrent NSCLCb 25 54.3
R1 after 1st surgerya 5 (1 in situ) 10.9
Metastases 2 4.3
Benign disease 3 6.6
Persistant atelectasis after initial 
surgery
1 2.2
Aspergilloma 1 2.2
Hemangioma 1 2.2
NCc 1 2.2
Location of the CP
Right/left lung completion 28/18 61/39
Upper/lower/both lobe(s) 21/24/1 46/52/2
Employed surgical techniques
Intrapericardial dissection 19 41
Chest wall resection 1 2
Vascular resection 0 0
Bronchial stump covered with a 
flap—all
17 37
Pleura 14 82
Pericardia 2 12
Muscle 1 6
Lymphadenectomy 38 83
Hospital care
Median hospital length of stay 
(days; min–max)
11 (7–169)
Median duration of thoracic 
drainage(days; min–max)
5 (2–15)
aDefined as the appearance of a cancer histologically different from that of the 
initial surgery, or histologically identical 5 yrs or more after the initial surgery.
bDefined as the appearance of a cancer histologically identical to that of the initial 
surgery within 5 yrs after the surgery.
cFirst surgery for aspergilloma.
NSCLC, non–small-cell lung cancer; R1, presence of microscopic residue after the 
initial surgery; CP, completion pneumonectomy; NC, not counted.
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FIGURE 1. Overall survival after 
completion pneumonectomy regard-
ing stage of the tumor. OS, overall 
survival.
Finally, there was no influence of antineoplastic neoadjuvant 
treatments on postoperative course, specifically for BPF, or 
pulmonary complications.
DISCUSSION
In our series, we found elevated rates of postoperative 
mortality (15.2%) and morbidity (55.6%) comparable with 
those of other published CP series (Table 5). Similarly, our 
CP mortality and morbidity rates were higher than those of 
standard pneumonectomy. This is again comparable with the 
majority of literature data,18,19 although some authors have 
found similar rates for the two interventions.12,14
For comparison, Thibout et al.20 studied patients who 
underwent pneumonectomy after chemotherapy; their popu-
lation was taken from the same thoracic surgery departments 
as ours (and involved the same surgeons). They found much 
lower rates of D90 mortality and BPF than we did: 9.2% ver-
sus 15.2% and 7% versus 13%, respectively. The percentage 
of patients transfused with more than two red blood packs 
was also much lower in the study by Thibout et al.20 than in 
ours (8% versus 35%), confirming the hemorrhagic nature 
of CP.5,21
The development of BPF or respiratory failure emerged 
in our study as a risk factor for postoperative mortality. This 
was not unexpected, as similar results have been reported in the 
literature for standard pneumonectomy.22,23 However, contrary 
to other studies,8,12,24 our study did not find that right-sidedness 
in CP was a mortality risk factor, but this may be explained 
by the small size of our study population. Furthermore, we 
did not find BPF to occur more frequently in the right lung 
than in the left. Surprisingly, our results indicated that inferior 
lobe CP was significantly associated with increased postop-
erative mortality. This aspect tends not to appear in the litera-
ture, with the exception of the study by Massard et al.4 who 
described increased, but statistically insignificant, periopera-
tive bleeding in inferior lobe CP. We hypothesize that this may 
be explained by the increased difficulty encountered when 
dissecting the root bronchus in the aftermath of a superior 
lobectomy. Whatever the case may be, this finding should be 
confirmed in a larger series.
Overall, our findings concerning long-term survival 
were encouraging. We did not perform a subgroup analysis 
comparing patients with lung metastases (n = 2) with the 
others, but the results of two retrospective studies focused 
uniquely on this population may suggest that CP is not a treat-
ment of choice for lung metastases, given the poor long-term 
survival and significant surgical risks.10,24
The study of prognosis factors is largely lacking in the 
literature: on one hand, the small number of patients in most 
series makes their statistical analysis difficult, and on the other, 
the studies on large cohorts have been predominantly focused 
on factors involved in BPF formation12,13 or postoperative mor-
tality.5,8 In multivariate analyses to determine risk factors for 
postoperative mortality, Chataigner et al.8 pointed to chronic 
renal failure, whereas Miller et al.5 indicated preoperative corti-
costeroid use and low preoperative hemoglobin. To our knowl-
edge, no studies have reported on factors influencing long-term 
survival. In our cohort, age older than 65 years, current smoker 
status at CP, and postoperative respiratory, cardiac, or parietal 
wound complications negatively influence long-term survival. 
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An original aspect is the significant prognostic influence that we 
found for parietal wound complications. An altered general or 
nutritional state present at CP and affecting the patient’s overall 
survival expectancy is a possible explanation for this.25
The precise evaluation of postoperative morbid-
ity (55.6%) is difficult retrospectively. Complications are 
dominated by respiratory and hemorrhagic disorders (the lat-
ter identified as significant perioperative bleeding indicated 
in the operative report or as significant bleeding observed 
postoperatively in the pneumonectomy cavity, necessitating 
or not a new surgical intervention) and the development of 
BPF. More than 43% of the patients in our study received 
perioperative transfusions, although we found no association 
between the number of transfusion packs and postopera-
tive mortality or long-term survival. This latter aspect is in 
contradiction with Thomas et al.26 who, in a larger cohort of 
pneumonectomy patients, found a significant link between 
the quantity of administered blood packs and postopera-
tive mortality. Nevertheless, these observations and those 
of other surgical series finding reduced long-term survival 
in transfused patients27–29 illustrate how the hemorrhagic 
nature of CP continues to be a major issue in patients oper-
ated for cancer.
Taking into account the early stage of lung cancer in 
the majority of our patients, less invasive therapeutic options 
such as chemoradiation and stereotactic radiotherapy could 
be discussed. Those techniques have lower morbidity and 
mortality,30 and long-term survival seems interesting.31,32 
However, long-term survival compared with redo surgery in 
case of local recurrence has not yet been evaluated prospec-
tively. Moreover, in their retrospective study on postrecur-
rence survival in completely resected stage I non–small-cell 
lung cancer with local recurrence, Hung et al.32 conclude that 
surgical resection should be considered in selected candidates 
with resectable local recurrent disease, because reoperated 
patients survived longer than patients treated with chemother-
apy and/or radiotherapy. A prospective study on the subject 
could be useful.
CONCLUSION
Our present retrospective study confirms that CP, com-
pared with standard pneumonectomy, is burdened with higher 
postoperative morbidity and mortality. We found that bleeding 
remains a major issue in this intervention as does the increased 
risk of BPF formation.
Risk factors for postoperative mortality detected were 
BPF formation, respiratory failure, more than two complica-
tions (among those analyzed in the study) and, more originally, 
CP in an inferior lobe. Prognosis factors affecting overall sur-
vival were age older than 65 years, current smoker status at 
CP, and postoperative respiratory, cardiac or parietal wound 
complications. Long-term survival remains encouraging and 
justifies the interest in this surgery.
CP is a rare surgical intervention; this explains the fre-
quently small populations in the various retrospective studies 
and thus their lack of statistical power to demonstrate congru-
ent prognostic factors. Improving current knowledge of these 
factors is nevertheless vital to permit a more precise selection 
of patients able to benefit from surgery. A meta-analysis to 
address these weaknesses would thus be a welcome addition 
to the literature.
TABLE 3. Postoperative Outcomes
Event n %
Mortality
Mortality before D30 6 13
Cause of death before D30 v
BPF 2 33.3
Respiratory failure 2 33.3
Unspecified 2 33.3
Mortality before D90 7 15.2
Complications / morbidity
Mean of blood cell packs transfused in 
perioperative period (min–max)a
1.97 (0–14)
Types of complicationsb
Hemorrhagec 11 24.4
Reoperationc 3 6.7
Cardiac complication (ischemic/
rhythmic)c
4 (2 / 2) 8.8
Respiratory failurec 11 24.4
Reintubation d 5 11.4
Parietal wound complicationc 3 6.7
Chylothoraxc 0 0
Recurrent nerve paralysisc 2 4.4
Empyemac 6 13
Thromboembolic diseasec 0 0
BPFc 6 13
Number of complications/patientc
None 20 44.4
≤ 2 13 28.9
> 2 12 26.1
Survival
Median OS* after CP (mos) (CI = 95%)d 30 (5.299–54.701)
Median OS after initial surgery (mos) 
(CI = 95%)a
79 (55.931–102.069)
Median OS after CP (mos), excluding 
postoperative deaths (CI = 95%)d
73 (0–155.643)
Median PFS* (mos) after CP (IC95%)e 16 (9.614–22.386)
Progression
Recurrence 21 50
Local 6 14.3
Distant 15 35.7
No recurrence 21 50
an = 20 patients transfused.
bComplications can be cumulative.
cn = 1 missing values.
d2 missing values (4 = 15 censored data).
en = 9 censored data.* OS, overall survival; PFS, progression-free survival; CI, 
confidence interval; CP, completion pneumonectomy; BPF, bronchopleural fistula. 
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TABLE 4. Factors Influencing Postoperative Mortality and Long-Term Survival
Factor Considered
Death D90 Overall Survival
n Dead/n in 
Cat. (%) p
Median (in mos) 
(95%CI) P
Hazard ratio (95% CI) 
by Cox Model p
Demographic criteria
Age (yrs)
< 65 5/34 (14.7%) 0.058 65.6 (18.1–112.2) 0.012 1 0.024
≥ 65 2/12 (16.7%) 21.2 (5.9–54.9) 2.7 (1.0–6.2)
Tobacco smoking status
Never or former smoker 3/29 (10.3%) 0.0216 44.9 (10.8–79.0) 0.013 1 0.035
Current smoker 4/17 (23.5%) 8.279 (3.6–13.0) 2.3 (1.1–4.9)
Surgery complications
Bronchopleural fistulaa
No 3/39 (7.7%) 0.024 44.9 (11.2–78.6) 0.347
Yes 3/6 (50%) 1.3 (0.0–26.4)
Pulmonary complication
No 0/34 (0%) < 0.00001 65.15 (34.3–96.0) < 0.00001 1 0.004
Yes 6/11 (54.5%) 1.3 (0.0–7.8) 5.1 (1.7–15.9)
Cardiac complicationa
No 4/41 (9.8%) 0.080 44.9 (10.1 – 79.8) 0.047 1 0.033
Yes 2/4 (50%) 0.6 (0.0 – 18.2) 3.4 (1.1–10.5)
Parietal wound complicationa 
No 5/42 (11.9%) 0.356 44.9 (5.9–84.0) 0.023 1 0.016
Yes 1/3 (33.3%) 4.9 (0.0–10.7) 5.4 (1.4–21.6)
Number of complicationsa
< 2 1/29 (3.4%) 0.017 44.9 (5.8–84.1) 0.231
≥ 2 5/16 (31.3%) 11.4 (0.0–28.0)
Surgery criteria
CP on the lower lobe 7/24 (29.2%) 0.01 21.2 (1.8–40.6) 0.390
CP elsewhere 0/22 (0%) 44.9 (10.6–79.2)
an = 1 missing value.
CI, confidence interval; CP, completion pneumonectomy 
TABLE 5.  Comparison between our Study and Others Concerning Postoperative Mortality (D90 Death in our Study), 
Bronchopleural Fistula Occurrence, and Intra and Postoperative Transfusions
Series Yr N
n with Malignant 
Disease
Postoperative Mortality Rate 
for Cancer Patients (%)
Bronchopleural 
Fistula (%)
Perioperative Blood 
Transfusions (%)
Mc Govern et al.2 1988 113 84 9.4 11.7 —
Grégoire et al.14 1993 60 41 11.6 13.3 —
Massard et al.4 1995 37 32 17.3 2.7 54
al-kattan et al.11 1995 38 26 0 0 —
Verhagen et al.7 1996 37 33 15.6 5.4 —
Muysoms et al.6 1998 138 80 13.2 4.3 —
Regnard et al.13 1999 80 62 6.4 3.8 66
Tronc et al.1 1999 77 57 10.5 10.4 —
Fujimoto et al.15 2001 66 49 2.3 7.6 —
Terzi et al.9 2002 59 59 3.4 — 52.4
Miller et al.5 2002 115 58 17.6 7 —
Guggino et al.12 2004 55 42 13.2 12.7 30
Jungraithmayr et al.3 2004 86 41 10 10.4 —
Chataigner et al.8 2007 69 47 12.8 10 19
Current study 2011 46 46 15 13 43
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